Entry Instance

HTTP 200 OK
Allow: GET, PUT, PATCH, DELETE, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "id": 1060867,
    "url": "https://info.mzalendo.com/api/v0.1/hansard/entries/1060867/?format=api",
    "text_counter": 71,
    "type": "speech",
    "speaker_name": "Endebess, JP",
    "speaker_title": "Hon. (Dr.) Robert Pukose",
    "speaker": {
        "id": 1458,
        "legal_name": "Robert Pukose",
        "slug": "robert-pukose"
    },
    "content": " Hon. Speaker, on behalf of the Member for Mumias East, Hon. Benjamin Washiali, I beg to ask the Cabinet Secretary for Health the following Question: (i) Could the Cabinet Secretary confirm whether the Oxford made - AstraZeneca COVID -19 vaccine ( AZD1222 ) against COVID-19 has any notable adverse side effects that include alleged cases of blood clotting amongst others when administered to persons, leading to banning of its use in some countries? (ii) Could the Cabinet Secretary explain the benefits of the said vaccine, the level of protection and efficacy to individuals after being administered, and indicate whether any adverse side effects have been reported in the country? (iii)Could the Cabinet Secretary explain how long the vaccin e underwent research in the country before being approved for administering to Kenyans considering the side effects allegedly being experienced in other countries? (iv) What is the Government’s position on the continuous use of the vaccine considering the slow pace of uptake by Kenyans and the side effects reported in other countries and is the Government making any plans to procure alternative vaccines for Kenyan citizens? Thank you Hon. Speaker. The electronic version of the Official Hansard Report is for information purposesonly. A certified version of this Report can be obtained from the Hansard Editor."
}